Chemical Property of Bazedoxifene acetate
Chemical Property:
- Vapor Pressure:6.33E-20mmHg at 25°C
- Melting Point:174-178°
- Boiling Point:694.4oC at 760 mmHg
- Flash Point:373.8oC
- PSA：95.16000
- LogP:6.35980
- Storage Temp.:?20°C
- Solubility.:DMSO: soluble15mg/mL, clear
- Hydrogen Bond Donor Count:3
- Hydrogen Bond Acceptor Count:6
- Rotatable Bond Count:7
- Exact Mass:530.27807232
- Heavy Atom Count:39
- Complexity:654
- Purity/Quality:
-
99% *data from raw suppliers
Bazedoxifene acetate *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O.CC(=O)O
- Recent ClinicalTrials:Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis
- Recent EU Clinical Trials:Open label, monocentric pilot study to evaluate safety and efficacy of Bazedoxifene in addition to Standard of Care in hospitalized COVID-19 patients suffering from moderate to severe Pneumonia
- Recent NIPH Clinical Trials:Administration test of dutasteride, bazedoxifene acetate and testosterone undecanoate preparation to healthy adult males
-
Uses
Bazedoxifene Acetate is a nonsteroidal selective estrogen receptor modulator (SERM). Bazedoxifene Acetate is used as an antiosteoporotic. Bazedoxifene acetate has been used to study its efficacy in inhibiting the interleukin-6 (IL-6)/IL-6R/glycoprotein 130 pathway and its effects on medulloblastoma cells.
-
Clinical Use
The selective estrogen receptor modulator bazedoxifene acetate was approved in Spain for the treatment
of osteoporosis in postmenopausal women. The drug was discovered by Wyeth (now Pfizer) and
licensed to Almirall. Clinical trials with bazedoxifene along with conjugated estrogens
demonstrated significant improvement in bone mineral density and prevented bone loss in
postmenopausal women without osteoporosis. It also reduces fracture risks among women with
postmenopausal osteroporosis.
